Dopamine transporter imaging is associated with long‐term outcomes in Parkinson's disease
Bernard Ravina(Voyager Therapeutics (United States)), Ira Shoulson(Baylor College of Medicine), Wendy R. Galpern(Janssen (United States)), Emily Flagg, James C. Beck(Parkinson's Foundation), Michael A. Schwarzschild(Massachusetts General Hospital), Anthony E. Lang(University of Toronto), Shirley Eberly(University of Rochester Medical Center), Roger Kurlan, Alberto Ascherio(Brigham and Women's Hospital), Caroline M. Tanner(University of California, San Francisco), Kenneth Marek(University of Pennsylvania), David Oakes(University of Rochester), Jennifer Harman(University of Rochester), F Béal(Georgetown University)
Cited by 135
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Vitamin E Consumption and the Risk of Coronary Heart Disease in Men
|New England Journal of Medicine|1993|2.4k
A polymorphic DNA marker genetically linked to Huntington's disease
|Nature|1983|2.3k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
|New England Journal of Medicine|2009|2.1k